\documentclass[a4paper,11pt] {article}
\hfuzz=100pt 
%\documentclass[a4paper,article,oneside,10pt]{memoir}
\usepackage[latin1]{inputenc}
\usepackage[T1]{fontenc}
%\usepackage[lucidasmallscale, nofontinfo]{lucimatx}
%\usepackage{times}
\usepackage{graphicx}
\usepackage{longtable}
\usepackage{here}
\usepackage{ctable}
\usepackage{pdflscape}
\usepackage{pst-tree}
\usepackage{longtable}
\usepackage{multirow}
\usepackage{dcolumn}
\usepackage{Sweave}
\usepackage{lscape}
\usepackage{geometry}
%\usepackage[pdftex,bookmarks=true,bookmarksnumbered=true,
%            hypertexnames=false,breaklinks=true,
%            linkbordercolor={0 0 1}]{hyperref}

%--------------

%
%\usepackage{fancyhdr}
%\pagestyle{empty}
%\pagestyle{fancy}
%\fancyhf{}
%%\renewcommand{\chaptermark}[1]{\markboth{\bsc{\chaptername~\thechapter{} :} #1}{}}
%%\renewcommand{\sectionmark}[1]{\markright{\thesection{} #1}}
%%\lfoot{Confidential, for the exclusive use of DMC members}
%%\renewcommand{\footrulewidth}{0.4pt}
%%\renewcommand{\headrulewidth}{0.4pt}
%%\renewcommand{\thepage}{\arabic{\page}}
%\setcounter{tocdepth}{5} % Dans la table des matieres
%\setcounter{secnumdepth}{5} % Avec un numero.
%%\mainmatter
%\pagenumbering{arabic}\setcounter{page}{1}
%\rhead{\thepage}
%\lhead{\leftmark}
%%\renewcommand{\thesection}{\Roman{section}}
%%\renewcommand{\thesection}{\Roman{section}}
%%\renewcommand{\thesection}{\Roman{section}}
%%\renewcommand{\thesubsection}{\thesection .\Alph{subsection}}
%
%--------------
\begin{document}
\title{Rapport  d'analyses statistiques}
\author{Axelle Dupont, sbim, Hopital Saint Louis, Paris}
\date{29 Mai 2017}

%------------------------------------------------------------






%-------------------------------------------------------------





\input{Rapport-concordance}


\setkeys{Gin}{width=1\textwidth}
\maketitle

%\pagestyle{protoc}
\tableofcontents
\pagebreak[4]
\listoftables
\listoffigures
%\SweaveOpts{eval=TRUE,echo=false,fig=TRUE}


\pagebreak[4]
%\chapter{Objectif}

\section{Objectives}

The primary objective of the study was to assess the survival, the risk of relapse and GVHD  of patients who underwent allogenic sterm-cell transplantation (alloSCT) for aggressive T-cell lymphomas. 
The second objective was to determine the variables associated with these outcomes.

\section{Methods}

A  retrospective analysis was conducted.A descriptive analysis of the variables recorded was perfomed. Different endpoints were defined : death, relapse ,Event-free survival(EFS) and Treatment related mortality (TRM).

Survival curves were estimated using Kaplan-Meier product-limit estimator. Factors associated with overall sur-vival were analyzed using Cox proportional hazards models. The proportional hazards assumption was checked by examination of Schoenfeld residuals.
For the different endpoints, univariable analyses were first carried out, then a multivariable analysis was used where all factors with P-value < 0.15 in the univariable analyses were considered. Factors where then sequentially removed from the adjusted model with a P-value cut- at 0.05. 
Survival is presented as estimate and 95\% confidence interval (95\% CI).


Competing risk survival analysis methods were applied to estimate the cumulative incidence (CIF) of developing events over time from alloSCT.These methods allow for the fact that a patient may experience an event which is different from that of interest. These events are known as competing risk events, and may preclude the onset of the event of interest, or may modify the probability of the onset of that event. In particular, a transplanted patient may die before a relapse occurs.
To test CIF between histopathologic groups we the test proposed by Gray. 

\pagebreak[4]
\section{Results}





\subsection{Descriptive results}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Wed May 24 18:25:09 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Age at diagnostic &  & 284 & 46.5 [36;55] \\ 
  Patient sex & Female & 93 & 32.75 \% \\ 
   & Male & 191 & 67.25 \% \\ 
  Age at diagnostic &  & 284 & 46.5 [36;55] \\ 
  Stage at diagnostic & I & 13 & 6.47 \% \\ 
   & II & 17 & 8.46 \% \\ 
   & III & 45 & 22.39 \% \\ 
   & IV & 126 & 62.69 \% \\ 
   & NA & 83 &  \\ 
  Stage at diagnostic & I-II & 113 & 39.79 \% \\ 
   & III-IV & 171 & 60.21 \% \\ 
  Subtypes & AITL & 82 & 28.87 \% \\ 
   & ALCL ALK- & 20 & 7.04 \% \\ 
   & ALCL ALK? & 2 & 0.7 \% \\ 
   & ALCL ALK+ & 21 & 7.39 \% \\ 
   & ATLL & 16 & 5.63 \% \\ 
   & EATL & 3 & 1.06 \% \\ 
   & HS & 12 & 4.23 \% \\ 
   & LGL & 1 & 0.35 \% \\ 
   & NK leukemia & 1 & 0.35 \% \\ 
   & NK/T nasal & 16 & 5.63 \% \\ 
   & NOS & 110 & 38.73 \% \\ 
  Subtypes & NOS & 110 & 38.73 \% \\ 
   & AITL & 82 & 28.87 \% \\ 
   & ALCL & 43 & 15.14 \% \\ 
   & ATLL & 16 & 5.63 \% \\ 
   & NK/T nasal & 16 & 5.63 \% \\ 
   & Others & 17 & 5.99 \% \\ 
  Centres & angers & 8 & 2.82 \% \\ 
   & Becquerel[941] & 4 & 1.41 \% \\ 
   & C.H.R.U Brest[659] & 2 & 0.7 \% \\ 
   & caen & 4 & 1.41 \% \\ 
   & CHU clermond ferrand & 7 & 2.46 \% \\ 
   & Geneve & 6 & 2.11 \% \\ 
   & Gustave Roussy[666] & 3 & 1.06 \% \\ 
   & H A Michallon[270] & 5 & 1.76 \% \\ 
   & H Bretonneau[272] & 3 & 1.06 \% \\ 
   & H Charles Nicolle[932] & 1 & 0.35 \% \\ 
   & H Claude Huriez[277] & 8 & 2.82 \% \\ 
   & H de l`ARCHET I[523]nice & 3 & 1.06 \% \\ 
   & H E Herriot[671] & 5 & 1.76 \% \\ 
   & H Haut-Leveque[267] & 31 & 10.92 \% \\ 
   & H Hautepierre[672] & 11 & 3.87 \% \\ 
   & H Jean Minjoz[233] & 5 & 1.76 \% \\ 
   & H La Miletrie[264] & 5 & 1.76 \% \\ 
   & H Mondor Hematol[252] & 4 & 1.41 \% \\ 
   & H Necker[160] & 9 & 3.17 \% \\ 
   & H Percy[665] & 4 & 1.41 \% \\ 
   & H Purpan[624] & 8 & 2.82 \% \\ 
   & H Sud/Pontchaillou[661] & 7 & 2.46 \% \\ 
   & H Sud[955] & 1 & 0.35 \% \\ 
   & Hotel Dieu[253] & 32 & 11.27 \% \\ 
   & liege & 8 & 2.82 \% \\ 
   & limoges & 3 & 1.06 \% \\ 
   & montpellier & 10 & 3.52 \% \\ 
   & nancy & 1 & 0.35 \% \\ 
   & Paoli Calmettes[230] & 39 & 13.73 \% \\ 
   & Pellegrin-Enfants[978] & 1 & 0.35 \% \\ 
   & Pitie-Salpetrriere[262] & 8 & 2.82 \% \\ 
   & St Antoine[775] & 10 & 3.52 \% \\ 
   & St Etienne[250] & 4 & 1.41 \% \\ 
   & St Louis[207] & 24 & 8.45 \% \\ 
   \hline
\hline
\caption{Patients} 
\label{tab:condi}
\end{longtable}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Wed May 24 18:25:09 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Previous auto & 0 & 191 & 67.25 \% \\ 
   & 1 & 93 & 32.75 \% \\ 
   Programme auto allo & 0 & 257 & 90.49 \% \\ 
   & 1 & 27 & 9.51 \% \\ 
  First graft relapse & 0 & 219 & 77.11 \% \\ 
   & 1 & 65 & 22.89 \% \\ 
   \hline
\hline
\caption{Treatment before alloSCT} 
\label{tab:avtg}
\end{longtable}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Wed May 24 18:25:09 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Age at graft &  & 284 & 49.5 [38;57] \\ 
  Age at graft & < 49 years & 139 & 48.94 \% \\ 
   & > 49 years & 145 & 51.06 \% \\ 
  Donor age &  & 263 & 28 [18;39] \\ 
  Donor sex & Female & 114 & 40.71 \% \\ 
   & Male & 166 & 59.29 \% \\ 
   & NA & 4 &  \\ 
  Delay diagnosis and allo SCT &  & 284 & 378.5 [213.2;710.8] \\ 
  >12 months delay & 0 & 149 & 52.46 \% \\ 
   & 1 & 135 & 47.54 \% \\ 
  Stage at diagnostic & I & 13 & 6.47 \% \\ 
   & II & 17 & 8.46 \% \\ 
   & III & 45 & 22.39 \% \\ 
   & IV & 126 & 62.69 \% \\ 
   & NA & 83 &  \\ 
  Disease status at transplant & CR/PR & 251 & 88.69 \% \\ 
   & PD & 32 & 11.31 \% \\ 
   & NA & 1 &  \\ 
  Disease status at transplant & CR & 175 & 61.84 \% \\ 
   & PD & 32 & 11.31 \% \\ 
   & PR & 76 & 26.86 \% \\ 
   & NA & 1 &  \\ 
  Disease status at transplant & CR (?) & 7 & 2.47 \% \\ 
   & CR1 & 94 & 33.22 \% \\ 
   & CR2 & 61 & 21.55 \% \\ 
   & CR3 & 13 & 4.59 \% \\ 
   & PD & 32 & 11.31 \% \\ 
   & PR (?) & 13 & 4.59 \% \\ 
   & PR1 & 39 & 13.78 \% \\ 
   & PR2 & 18 & 6.36 \% \\ 
   & PR3 & 5 & 1.77 \% \\ 
   & PR4 & 1 & 0.35 \% \\ 
   & NA & 1 &  \\ 
  Karnofsky &  & 263 & 90 [80;100] \\ 
  Karnofsky & 100 & 92 & 34.98 \% \\ 
   & 40 & 1 & 0.38 \% \\ 
   & 50 & 4 & 1.52 \% \\ 
   & 60 & 1 & 0.38 \% \\ 
   & 70 & 9 & 3.42 \% \\ 
   & 80 & 70 & 26.62 \% \\ 
   & 90 & 86 & 32.7 \% \\ 
   & NA & 21 &  \\ 
  No of lines before alloSCT & >=4 & 24 & 9.45 \% \\ 
   & 1 & 73 & 28.74 \% \\ 
   & 2 & 92 & 36.22 \% \\ 
   & 3 & 65 & 25.59 \% \\ 
   & NA & 30 &  \\ 
  Donnor related & 0 & 149 & 52.46 \% \\ 
   & 1 & 135 & 47.54 \% \\ 
  HLA match & 1 & 231 & 81.34 \% \\ 
   & 0 & 53 & 18.66 \% \\ 
  HLA match & Identical sibling & 128 & 45.07 \% \\ 
   & Matched unrelated & 103 & 36.27 \% \\ 
   & Mismatched relative & 7 & 2.46 \% \\ 
   & Mismatched unrelated & 13 & 4.58 \% \\ 
   & Unrelated CB & 33 & 11.62 \% \\ 
  sex of patient/donnor & M/F & 47 & 16.55 \% \\ 
   & Others & 237 & 83.45 \% \\ 
  CMV serostatus of patient/donnor & autres & 232 & 81.69 \% \\ 
   & neg/pos & 52 & 18.31 \% \\ 
  Source of stem cells & BM & 49 & 17.25 \% \\ 
   & CB & 33 & 11.62 \% \\ 
   & PB & 202 & 71.13 \% \\ 
  TBI & No & 161 & 56.69 \% \\ 
   & Yes & 123 & 43.31 \% \\ 
  conditioning Intensity & MAC & 106 & 38.13 \% \\ 
   & NMA & 27 & 9.71 \% \\ 
   & RIC & 145 & 52.16 \% \\ 
   & NA & 6 &  \\ 
  Conditioning & BEAM & 1 & 0.36 \% \\ 
   & BEAM + Campath & 1 & 0.36 \% \\ 
   & BU CY  & 4 & 1.42 \% \\ 
   & BU CY + FLU+ ATG & 1 & 0.36 \% \\ 
   & BU CY ATG & 1 & 0.36 \% \\ 
   & EDX ATG & 0 & 0 \% \\ 
   & ENX TBI 2gray & 1 & 0.36 \% \\ 
   & FLU ATG & 3 & 1.07 \% \\ 
   & FLU BU 1+ ATG & 3 & 1.07 \% \\ 
   & FLU BU 2 & 1 & 0.36 \% \\ 
   & FLU BU 2+ ATG & 73 & 25.98 \% \\ 
   & FLU BU 3+ ATG & 21 & 7.47 \% \\ 
   & FLU BU 4+ ATG & 10 & 3.56 \% \\ 
   & FLU BU EDX & 8 & 2.85 \% \\ 
   & FLU BU EDX +ATG & 6 & 2.14 \% \\ 
   & FLU EDX & 1 & 0.36 \% \\ 
   & FLU EDX ATG & 3 & 1.07 \% \\ 
   & FLU EDX MEL & 1 & 0.36 \% \\ 
   & FLU ENX TBI 2gray & 24 & 8.54 \% \\ 
   & FLU ENX TBI 4gray & 2 & 0.71 \% \\ 
   & FLU ENX TBI 6gray & 1 & 0.36 \% \\ 
   & FLU ENX TBI 6gray + campath & 1 & 0.36 \% \\ 
   & FLU MEL & 12 & 4.27 \% \\ 
   & FLU MEL + campath & 4 & 1.42 \% \\ 
   & FLU MEL + Campath & 1 & 0.36 \% \\ 
   & FLU MEL ATG & 1 & 0.36 \% \\ 
   & FLU MEL TBI 2gray & 1 & 0.36 \% \\ 
   & FLU TBI 2gray & 21 & 7.47 \% \\ 
   & FLU TBI 2gray ATG & 1 & 0.36 \% \\ 
   & FLU Tbi 8 gray & 1 & 0.36 \% \\ 
   & MEL 140 TBI 10 gray & 1 & 0.36 \% \\ 
   & MEL TBI VP16 & 1 & 0.36 \% \\ 
   & TB2F & 2 & 0.71 \% \\ 
   & TBI 12 gray & 1 & 0.36 \% \\ 
   & TBI 2gray & 1 & 0.36 \% \\ 
   & TBI EDX & 49 & 17.44 \% \\ 
   & TBI EDX +ATG & 11 & 3.91 \% \\ 
   & TBI EDX FLU & 5 & 1.78 \% \\ 
   & Thiotepa etoposide TBI12 gray & 1 & 0.36 \% \\ 
   & NA & 3 &  \\ 
  Cells manipulation & none & 275 & 97.86 \% \\ 
   & yes & 6 & 2.14 \% \\ 
   & NA & 3 &  \\ 
  No of donnors & 1 & 261 & 91.9 \% \\ 
   & 2 & 23 & 8.1 \% \\ 
   \hline
\hline
\caption{AlloSCT} 
\label{tab:g}
\end{longtable}

% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Wed May 24 18:25:09 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Agvhd & 0 & 141 & 49.65 \% \\ 
   & 1 & 143 & 50.35 \% \\ 
  Agvhd grade & No aGvHD present (Grade 0) & 141 & 49.65 \% \\ 
   & Grade I & 49 & 17.25 \% \\ 
   & Grade II & 46 & 16.2 \% \\ 
   & Grade III & 24 & 8.45 \% \\ 
   & Grade IV & 17 & 5.99 \% \\ 
   & Present, grade unknown & 7 & 2.46 \% \\ 
  Cgvhd & 0 & 187 & 65.85 \% \\ 
   & 1 & 97 & 34.15 \% \\ 
  Cgvhd grade & deces avant J100 & 41 & 14.44 \% \\ 
   & extensive & 38 & 13.38 \% \\ 
   & limited & 55 & 19.37 \% \\ 
   & no cGvh & 146 & 51.41 \% \\ 
   & unknown & 4 & 1.41 \% \\ 
  Engrafted & deces avant J30 & 5 & 1.76 \% \\ 
   & engrafted & 271 & 95.42 \% \\ 
   & lost graft & 2 & 0.7 \% \\ 
   & no engraftment & 6 & 2.11 \% \\ 
  Cause of death & HSCT-GVHd & 21 & 19.63 \% \\ 
   & HSCT-GVHd + infection & 3 & 2.8 \% \\ 
   & HSCT-infection & 27 & 25.23 \% \\ 
   & HSCT-toxicity & 4 & 3.74 \% \\ 
   & HSCT related & 3 & 2.8 \% \\ 
   & HSCT related ILD & 1 & 0.93 \% \\ 
   & HSCT related MAT & 1 & 0.93 \% \\ 
   & HSCT related MOF & 2 & 1.87 \% \\ 
   & HSCT related MVO & 1 & 0.93 \% \\ 
   & HSCT related pneumopathie interstititelle & 2 & 1.87 \% \\ 
   & HSCT related PTLD & 1 & 0.93 \% \\ 
   & HSCT related SDRA & 1 & 0.93 \% \\ 
   & Other & 1 & 0.93 \% \\ 
   & Relapse or progression of original disease & 37 & 34.58 \% \\ 
   & Secondary malignancy & 1 & 0.93 \% \\ 
   & Unknown & 1 & 0.93 \% \\ 
   & NA & 177 &  \\ 
  Best reponse after SCT & CR & 245 & 86.88 \% \\ 
   & Not evaluable & 4 & 1.42 \% \\ 
   & Not evaluated & 3 & 1.06 \% \\ 
   & PD & 14 & 4.96 \% \\ 
   & PR & 16 & 5.67 \% \\ 
   & NA & 2 &  \\ 
  Relapse/progression & continuous progression & 28 & 9.93 \% \\ 
   & No & 217 & 76.95 \% \\ 
   & Non applicable  & 3 & 1.06 \% \\ 
   & yes & 34 & 12.06 \% \\ 
   & NA & 2 &  \\ 
  Death & alive & 177 & 62.32 \% \\ 
   & dead & 107 & 37.68 \% \\ 
   \hline
\hline
\caption{Post-AlloSCT Response} 
\label{tab:pg}
\end{longtable}


\pagebreak[4]
\newgeometry{bmargin=1cm}
\begin{landscape}





\end{landscape}

\restoregeometry

\subsection{Survival analysis}
Median follow-up from the date of AlloSCT was 20.35 (range 0.03 to 113.77). OS at 1 years was 0.68 (95 \% 0.63 - 0.74), was 0.64 (95 \% 0.59 - 0.7) at 2 years
.OS at 4 years was 0.57 (95 \% 0.5 - 0.64).
\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig1}
\end{center}
\caption{Overall survival}
\label{fig1}
\end{figure}

\pagebreak
EFS at 1 years was 0.54 (95 \% 0.48 - 0.6), was 0.49 (95 \% 0.43 - 0.55) at 2 years. EFS at 4 years was 0.42 (95 \% 0.36 - 0.5).

\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig2}
\end{center}
\caption{Event-free survival}
\label{fig2}
\end{figure}

\pagebreak
PFS at 1 years was 0.73 (95 \% 0.65 - 0.83), was 0.68 (95 \% 0.59 - 0.78) at 2 years. PFS at 4 years was 0.66 (95 \% 0.56 - 0.77).

\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig3}
\end{center}
\caption{Progression-free survival}
\label{fig3}
\end{figure}


\begin{figure}
\begin{center}
\includegraphics{Rapport-fig4}
\end{center}
\caption{Relapse in patients with a complete remission post alloSCT)}
\label{fig4}
\end{figure}


\begin{figure}
\begin{center}
\includegraphics{Rapport-fig5}
\end{center}
\caption{CIF of Related HSCT Death and Non-related HSCT Death}
\label{fig5}
\end{figure}


CIF for relapse/progression at 1 years was 0.18, at 2 years  0.19.
CIF for death without relapse or progression at 1 years was 0.19, at 2 years  0.22. 

\begin{figure}
\begin{center}
\includegraphics{Rapport-fig6}
\end{center}
\caption{CIF of relapse or progression and death without relapse or progression}
\label{fig6}
\end{figure}


\begin{figure}
\begin{center}
\includegraphics{Rapport-fig7}
\end{center}
\caption{CIF of relapse and death without relapse (in patients with a complete remission post alloSCT)}
\label{fig7}
\end{figure}




\end{document}
